We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FOLLOW-ON BIOLOGICS LIKELY TO COME FROM BIOTECH FIRMS
FOLLOW-ON BIOLOGICS LIKELY TO COME FROM BIOTECH FIRMS
June 29, 2004
While generic drugmakers are leading the charge for follow-on biologics, existing biotech brand firms likely will be the first to go after the nearly $10 billion worth of biologic products going off patent in the next few years, experts say.